Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.

Driessen, M T; Whalen, J; Buguth, B Seewoodharry; Vallejo-Aparicio, L A; Naya, I P; Asukai, Y; Alcázar-Navarrete, B; Miravitlles, M; García-Río, F; Risebrough, N A

Driessen, M T; Whalen, J; Buguth, B Seewoodharry; Vallejo-Aparicio, L A; Naya, I P; Asukai, Y; Alcázar-Navarrete, B; Miravitlles, M; García-Río, F; Risebrough, N A.

Affiliation

Driessen MT; Value Evidence and Outcomes, GSK, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK.
Whalen J; ICON Health Economics, ICON plc, Abingdon, UK.
Buguth BS; ICON Health Economics, ICON plc, Abingdon, UK.
Vallejo-Aparicio LA; Departamento de Evaluación de Medicamentos, GSK, Tres Cantos, Madrid, Spain.
Naya IP; Global Respiratory Franchise, GSK, Brentford, Middlesex, UK.
Asukai Y; Value Evidence and Outcomes, GSK, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK. yumiko.x.asukai@gsk.com.
Alcázar-Navarrete B; Hospital de Alta Resolución de Loja, Granada, Spain.
Miravitlles M; Pneumology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
García-Río F; Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Risebrough NA; ICON Health Economics, ICON, Toronto, ON, Canada.

Respir Res ; 20(1): 18, 2019 01 28.

Article in En | MEDLINE | ID: mdl-30691468

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Evaluation_studies / Health_economic_evaluation Language: En Journal: Respir Res Year: 2019 Document type: Article Affiliation country: Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google